Physician profile
Daniel S Chang
NPI 1962728022
$4,356.96
in general payments reported to CMS, 2019-2025
22 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $110 · 2021: $34.50 · 2022: $651 · 2023: $935 · 2024: $1,014 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,074 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,074.24 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,593.06 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $628.27 | 2019-2025 | |
| Janssen Biotech, INC. | $354.06 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $313.98 | 2019-2025 | |
| Pfizer INC. | $260.18 | 2019-2025 | |
| Galderma Laboratories, L.P. | $213.78 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $161.74 | 2019-2024 | Adbry |
| Incyte Corporation | $131.99 | 2022-2025 | Opzelura |
| Ucb, INC. | $126.95 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $96.38 | 2023-2025 | Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.04 | 2023 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $59.50 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $57.14 | 2019-2022 | |
| Prugen, INC. Pharmaceuticals | $53.64 | 2020 | |
| Krystal Biotech INC | $50.60 | 2023-2025 | Vyjuvek |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $48.45 | 2025 | Ycanth |
| Lilly USA, LLC | $34.61 | 2024 | Taltz, Olumiant |
| Amgen INC. | $31.12 | 2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.30 | 2025 | Cabtreo, Siliq, Jublia |
| Arcutis Biotherapeutics, INC. | $16.42 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $15.77 | 2023 | Vtama |
| Organon LLC | $14.98 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.